Rezolute, Inc.

37 articles with Rezolute, Inc.

• Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

  6/1/2022

  Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer.

• Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

  5/12/2022

  Rezolute, Inc. announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022.

• Rezolute, Inc. Announces Closing of Registered Direct Offering - May 04, 2022

  5/4/2022

  Rezolute, Inc. announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share.

• Rezolute to Host Corporate Update Call on May 4, 2022Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET

  5/4/2022

  Rezolute, Inc. announced that management will be hosting a corporate update call.

• Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

  5/1/2022

  Rezolute, Inc. announced positive results from its Phase 2b RIZE study of RZ358 in patients with congenital hyperinsulinism, which were unveiled today in a late-breaking oral presentation at the Pediatric Endocrine Society 2022 Annual Meeting.

• RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022

  4/26/2022

  Rezolute, Inc. (Nasdaq: RZLT), today announced a late-breaking oral presentation of its Phase 2b RIZE Study Topline Data of RZ358 in congenital hyperinsulinism (HI) at the upcoming Pediatric Endocrine Society 2022 Annual Meeting on May 1, 2022.

• Rezolute Joins the Rare Disease Company Coalition

  3/29/2022

  Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that it has joined the Rare Disease Company Coalition.

• 

  Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

  3/28/2022

  Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

• Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

  3/23/2022

  Rezolute, Inc. today announced positive data from its Phase 2b RIZE study of RZ358.

• Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DMEPhase 2 proof-of-concept study anticipated in 2H 2022

  2/22/2022

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced topline data from its Phase 1b multiple-ascending dose (MAD) study of RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular edema (DME).

• Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company ProgressTopline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022

  2/9/2022

  Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced its financial results for the second quarter of fiscal 2022 ended December 31, 2021.

• Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

  11/12/2021

  Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced its financial results for the first quarter of fiscal 2022 ended September 30, 2021.

• Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

  10/13/2021

  Rezolute, Inc. announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant.

• Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

  10/12/2021

  Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.

• Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

  9/22/2021

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today presented results from a natural history study designed to quantify the extent of hypoglycemia in congenital hyperinsulinism (HI) patients on standard of care therapies.

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

  9/15/2021

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full year ended June 30, 2021.

• Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

  9/9/2021

  Rezolute, Inc. (Nasdaq: RZLT), today announced that it has begun dosing patients in the second cohort of its Phase 2b clinical trial of RZ358 (RIZE).

• Rezolute to Participate in Upcoming Virtual Healthcare Conferences in September 2021

  9/7/2021

  Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.